MX2018007361A - Moléculas pequeñas para inhibir la actividad de quimiocinas, la actividad de una cinasa y/o el crecimiento de células cancerosas. - Google Patents

Moléculas pequeñas para inhibir la actividad de quimiocinas, la actividad de una cinasa y/o el crecimiento de células cancerosas.

Info

Publication number
MX2018007361A
MX2018007361A MX2018007361A MX2018007361A MX2018007361A MX 2018007361 A MX2018007361 A MX 2018007361A MX 2018007361 A MX2018007361 A MX 2018007361A MX 2018007361 A MX2018007361 A MX 2018007361A MX 2018007361 A MX2018007361 A MX 2018007361A
Authority
MX
Mexico
Prior art keywords
activity
cancer cells
small molecules
cells growth
kinase
Prior art date
Application number
MX2018007361A
Other languages
English (en)
Inventor
Peled Amnon
Abraham Michal
Eizenberg Orly
Original Assignee
Biokine Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biokine Therapeutics Ltd filed Critical Biokine Therapeutics Ltd
Publication of MX2018007361A publication Critical patent/MX2018007361A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

En el presente documento se proporcionan compuestos capaces de o que se pueden usar en la inducción de muerte de células cancerosas y/o la modulación de una actividad biológica de una quimiocina, por ejemplo, migración celular y/o el tratamiento de enfermedades y trastornos asociados a una actividad biológica de una quimiocina y/o migración celular y/o la inhibición de una cinasa y/o en el tratamiento de una enfermedad o un trastorno asociados a una actividad de una cinasa, tal como cáncer y enfermedades y trastornos inflamatorios. Los compuestos se representan de forma colectiva por las fórmulas Ia o Ib:(ver formulas) Fórmula Ia Fórmula Ib en las que A, B D, E, G y R1-R5 R5 son como se ha definido en la memoria descriptiva.
MX2018007361A 2015-12-17 2016-12-15 Moléculas pequeñas para inhibir la actividad de quimiocinas, la actividad de una cinasa y/o el crecimiento de células cancerosas. MX2018007361A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562268586P 2015-12-17 2015-12-17
PCT/IL2016/051347 WO2017103932A1 (en) 2015-12-17 2016-12-15 Small molecules for inhibiting chemokine activity, a kinase activity and/or cancer cells growth

Publications (1)

Publication Number Publication Date
MX2018007361A true MX2018007361A (es) 2019-05-16

Family

ID=59056164

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020011500A MX2020011500A (es) 2015-12-17 2016-12-15 Moléculas pequeñas para inhibir la actividad de quimiocinas, la actividad de una cinasa y/o el crecimiento de células cancerosas.
MX2018007361A MX2018007361A (es) 2015-12-17 2016-12-15 Moléculas pequeñas para inhibir la actividad de quimiocinas, la actividad de una cinasa y/o el crecimiento de células cancerosas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2020011500A MX2020011500A (es) 2015-12-17 2016-12-15 Moléculas pequeñas para inhibir la actividad de quimiocinas, la actividad de una cinasa y/o el crecimiento de células cancerosas.

Country Status (12)

Country Link
US (2) US11129824B2 (es)
EP (2) EP3741432B1 (es)
JP (1) JP6941611B2 (es)
KR (1) KR20180100135A (es)
CN (1) CN108699000B (es)
AU (2) AU2016371466B2 (es)
CA (1) CA3008107C (es)
DK (1) DK3390364T3 (es)
ES (2) ES2818531T3 (es)
IL (1) IL260081B (es)
MX (2) MX2020011500A (es)
WO (1) WO2017103932A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3390378B1 (en) 2015-12-17 2022-03-30 AlonBio Ltd. Small molecules against cancer
DK3390364T3 (da) 2015-12-17 2020-10-12 Biokine Therapeutics Ltd Små molekyler til hæmning af kemokinaktivitet og/eller cancercellevækst
JP2022532258A (ja) 2019-05-15 2022-07-13 アロンバイオ リミテッド 癌の治療、ケモカイン活性の阻害および／または細胞死の誘導のための小分子
JP2020193249A (ja) * 2019-05-27 2020-12-03 信越化学工業株式会社 量子ドット、量子ドット組成物、波長変換材料、波長変換フィルム、バックライトユニット及び画像表示装置
WO2023244619A2 (en) * 2022-06-13 2023-12-21 Mayo Foundation For Medical Education And Research Flavonoid compounds and methods and materials for using flavonoid compounds to treat fibrotic conditions

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
WO1992020642A1 (en) 1991-05-10 1992-11-26 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
FR2682107B1 (fr) * 1991-10-03 1995-04-21 Orstom Inst Fs Rech Scient Quinoleines 2-substituees pour le traitement des leishmanioses.
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
KR19990082463A (ko) 1996-02-13 1999-11-25 돈 리사 로얄 혈관 내피 성장 인자 억제제로서의 퀴나졸린유도체
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
HUP0102793A3 (en) 1998-05-28 2002-07-29 Parker Hughes Inst St Paul Quinazolines for treating brain tumor and medicaments containing them
FR2781218B1 (fr) 1998-07-15 2001-09-07 Lafon Labor Compositions pharmaceutiques comprenant des 2-quinolones
WO2000010981A1 (en) 1998-08-21 2000-03-02 Parker Hughes Institute Quinazoline derivatives
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6258820B1 (en) 1999-03-19 2001-07-10 Parker Hughes Institute Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines
ES2270867T3 (es) 1999-09-23 2007-04-16 Astrazeneca Ab Compuestos de quinazolina terapeuticos.
PT1257537E (pt) * 2000-01-24 2007-08-03 Astrazeneca Ab Compostos terapêuticos morfolino-substituídos.
GB0028702D0 (en) 2000-11-24 2001-01-10 Novartis Ag Organic compounds
US20030221931A1 (en) 2002-02-28 2003-12-04 Steve Marsh Sliding device
WO2005108431A1 (en) 2004-05-04 2005-11-17 University Of Kentucky Research Foundation Methods and compositions for the treatment of ocular neovascularization
WO2007052173A2 (en) 2005-02-23 2007-05-10 Endocube S.A.S. Activity of thap-family chemokine-binding domains
JP2009531022A (ja) 2006-02-17 2009-09-03 ラパポート ファミリー インスティテュート フォー リサーチ イン ザ メディカル サイエンシーズ Ｃｃｒ５／ｃｃｒ５リガンド関連疾患を治療するための分子およびその使用方法
US20100249184A1 (en) 2007-03-16 2010-09-30 Mount Sinai School Of Medicine Induction and/or maintenance of tumor dormancy by disruption of urokinase plasminogen activator receptor-integrin interaction
CN101202347A (zh) 2007-11-22 2008-06-18 山东神工海特电子科技有限公司 具有金属骨架正极的1.5v锂二硫化铁扣式电池
CN106928194B (zh) 2009-06-12 2019-11-12 Abivax公司 用于治疗过早衰老和尤其是早衰的化合物
HUE025294T2 (en) 2009-06-15 2016-02-29 Biokine Therapeutics Ltd New chemokine-binding polypeptides that are able to inhibit the process of autoimmunity, inflammation and cancer
WO2012119978A1 (en) * 2011-03-07 2012-09-13 Glaxosmithkline Llc Quinolinone derivatives
WO2016092544A1 (en) 2014-12-09 2016-06-16 Biokine Therapeutics Ltd. Compositions and methods for the treatment of ocular diseases
DK3390364T3 (da) 2015-12-17 2020-10-12 Biokine Therapeutics Ltd Små molekyler til hæmning af kemokinaktivitet og/eller cancercellevækst
EP3390378B1 (en) 2015-12-17 2022-03-30 AlonBio Ltd. Small molecules against cancer
JP2022532258A (ja) 2019-05-15 2022-07-13 アロンバイオ リミテッド 癌の治療、ケモカイン活性の阻害および／または細胞死の誘導のための小分子

Also Published As

Publication number Publication date
ES2818531T3 (es) 2021-04-13
MX2020011500A (es) 2020-12-07
AU2020204524B9 (en) 2022-02-03
AU2016371466B2 (en) 2020-04-09
RU2018125293A (ru) 2020-01-17
EP3741432B1 (en) 2023-05-10
CA3008107A1 (en) 2017-06-22
WO2017103932A1 (en) 2017-06-22
CN108699000B (zh) 2021-09-21
JP2019502699A (ja) 2019-01-31
EP3390364B1 (en) 2020-07-15
KR20180100135A (ko) 2018-09-07
WO2017103932A9 (en) 2017-08-24
CA3008107C (en) 2023-06-27
IL260081B (en) 2021-09-30
AU2020204524A1 (en) 2020-07-30
EP3390364A1 (en) 2018-10-24
US20220008407A1 (en) 2022-01-13
EP3390364A4 (en) 2018-10-24
CN108699000A (zh) 2018-10-23
BR112018012306A2 (pt) 2018-12-04
AU2016371466A1 (en) 2018-07-19
ES2951385T3 (es) 2023-10-20
IL260081A (en) 2018-07-31
US20190336492A1 (en) 2019-11-07
AU2020204524B2 (en) 2022-01-20
RU2018125293A3 (es) 2020-04-06
DK3390364T3 (da) 2020-10-12
US11129824B2 (en) 2021-09-28
JP6941611B2 (ja) 2021-09-29
EP3741432A1 (en) 2020-11-25

Similar Documents

Publication Publication Date Title
MX2020005463A (es) Anticuerpos anti grupo de diferenciacion 47 (anti-cd47) y sus usos para tratar cancer.
MX2018007361A (es) Moléculas pequeñas para inhibir la actividad de quimiocinas, la actividad de una cinasa y/o el crecimiento de células cancerosas.
PH12015502610A1 (en) Compounds for kinase modulation, and indications therefor
BR112018073861A2 (pt) métodos de terapia de genes para doenças e condições relacionadas com a idade
PH12015501370B1 (en) Compounds and methods for kinase modulation, and indications therefor
MX2017004128A (es) Derivados de diarilurea como inhibidores de quinasa p38.
CL2015002194A1 (es) Inhbidores de erk y sus usos
MY188447A (en) Indazole compounds as fger kinase inhibitor, preparation and use thereof
EA201791133A1 (ru) Ингибиторы erk
EA201690713A1 (ru) Гетероциклические соединения и их применения
EA201690881A1 (ru) Соединения-ингибиторы аутотаксина
EA201791624A1 (ru) СОЕДИНЕНИЯ ДЛЯ УЛУЧШЕНИЯ СПЛАЙСИНГА мРНК
MX2015002044A (es) Pirazolil-ureas como inhibidores de quinasa.
MX2015013945A (es) Derivados de urea utiles como inhibidores de quinasa.
MX2017017049A (es) Anticuerpos anti antigeno de celulas nk y linfocitos t y b (ntb-a) y composiciones y metodos relacionados.
CL2010001538A1 (es) Compuestos derivados de pirazolo-quinazolina sustituidos, moduladores de la actividad de las proteinas quinasas; composicion farmaceutica; y su uso para el tratamiento del cancer, o un trastorno proliferativo celular.
GEP20166489B (en) 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors
MX2018014366A (es) Interfaces de proteina.
BR112018012913A2 (pt) tratamento in situ de sementes em sulco
BR112018008931A8 (pt) ?compostos para tratamento de distúrbios hipoproliferativos?
EP3476401A4 (en) CELL DEATH INDUCER, CELL PROLIFERATION INHIBITOR AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF A DISEASE ASSOCIATED WITH AN ABNORMAL CELL PROLIFERATION
IL288144A (en) Compounds to treat cancer, to inhibit chemokines and/or to kill cells
MX2017006491A (es) Composiciones y métodos para la modulación de la actividad at2r.
AR085105A1 (es) Dosificacion para tratamiento con anticuerpos anti-dominio 7 de tipo de factor de crecimiento epidermico (anti-egfl7)
ES2396764A1 (es) FÁRMACOS INHIBIDORES DE p38 Y APLICACIONES.